Insider Selling: Icon (NASDAQ:ICLR) Director Sells $138,167.89 in Stock

Icon Plc (NASDAQ:ICLR) Director Anne Clem Whitaker sold 841 shares of Icon stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $164.29, for a total transaction of $138,167.89. Following the transaction, the director owned 891 shares in the company, valued at approximately $146,382.39. The trade was a 48.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Stock Up 1.0%

Shares of ICLR traded up $1.59 during mid-day trading on Wednesday, reaching $167.17. The company’s stock had a trading volume of 804,300 shares, compared to its average volume of 1,385,101. The company has a market cap of $12.80 billion, a price-to-earnings ratio of 39.24, a price-to-earnings-growth ratio of 6.88 and a beta of 1.21. The business has a fifty day moving average of $161.47 and a 200 day moving average of $134.31. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.23. Icon Plc has a 1 year low of $66.57 and a 1 year high of $203.91.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.55 by $0.01. The business had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $2 billion. Icon had a return on equity of 8.02% and a net margin of 3.99%.Icon’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.26 earnings per share. As a group, analysts forecast that Icon Plc will post 9.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

ICLR has been the subject of a number of research analyst reports. Mizuho increased their price target on shares of Icon from $180.00 to $190.00 and gave the stock an “outperform” rating in a research report on Friday, June 26th. Royal Bank Of Canada upgraded shares of Icon from a “sector perform” rating to an “outperform” rating and upped their price objective for the company from $126.00 to $185.00 in a research note on Thursday, June 25th. JPMorgan Chase & Co. increased their target price on shares of Icon from $130.00 to $155.00 and gave the stock a “neutral” rating in a research report on Thursday, June 25th. Robert W. Baird set a $194.00 price target on shares of Icon in a report on Friday, July 31st. Finally, DA Davidson set a $164.00 price target on shares of Icon in a research note on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $170.40.

Key Headlines Impacting Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Icon’s latest quarterly results modestly exceeded expectations: adjusted EPS was $2.56 versus the $2.55 consensus, while revenue reached $2.06 billion, above the $2.00 billion estimate and up 2.3% year over year. Analysts expect approximately $9.57 in full-year EPS, providing a fundamental support for the stock.
• Positive Sentiment: Recent analyst actions have generally been constructive. BMO Capital Markets raised its price target to $187 and Mizuho increased its target to $190, both maintaining outperform ratings. The consensus target is $170.40, modestly above the latest trading level, although the overall consensus rating remains “Hold.”
• Positive Sentiment: Short interest is reported at zero shares, indicating no measurable bearish short-selling pressure or potential forced-selling overhang.
• Neutral Sentiment: CEO Barry Balfe sold 382 shares worth about $62,675, while CFO Nigel Clerkin sold 2,267 shares worth approximately $372,445. Directors John Climax and Linda Grais each sold 841 shares at about $164.29. The filings state that all transactions were made to cover tax-withholding obligations tied to vested equity awards, reducing their usefulness as a signal of declining confidence. SEC insider transaction filing
• Negative Sentiment: Despite the revenue beat, quarterly EPS fell from $3.26 a year earlier, and Icon’s reported net margin was only 3.99%. The stock also carries a high valuation, with a price-to-earnings ratio near 39 and a PEG ratio of 6.88, leaving it sensitive to any slowdown in clinical-research demand or earnings growth.

Institutional Investors Weigh In On Icon

Large investors have recently made changes to their positions in the company. Wellington Management Group LLP raised its position in Icon by 26.6% during the third quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock valued at $811,499,000 after acquiring an additional 975,268 shares in the last quarter. Orbis Allan Gray Ltd lifted its stake in Icon by 1.8% in the fourth quarter. Orbis Allan Gray Ltd now owns 4,214,661 shares of the medical research company’s stock valued at $767,996,000 after acquiring an additional 75,843 shares during the last quarter. Invesco Ltd. grew its position in Icon by 9.6% in the fourth quarter. Invesco Ltd. now owns 3,756,896 shares of the medical research company’s stock worth $684,582,000 after acquiring an additional 329,266 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Icon by 10.3% during the 1st quarter. Principal Financial Group Inc. now owns 3,311,771 shares of the medical research company’s stock worth $366,481,000 after purchasing an additional 310,236 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of Icon by 8.7% during the 4th quarter. Franklin Resources Inc. now owns 2,993,336 shares of the medical research company’s stock worth $545,410,000 after purchasing an additional 239,808 shares during the last quarter. Institutional investors own 95.61% of the company’s stock.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.